Alexion’s Quality Problems Deepen With New 483

Drug Industry Daily
A A
More than a year after being warned by the FDA for poor quality, Alexion Pharmaceuticals received a fresh Form 483 for problems surrounding gowning procedures and other quality issues.

To View This Article:

Login

Subscribe To Drug Industry Daily